Biogen Idec Revenue Quarterly YoY Growth:
9.53% for March 31, 2013Biogen Idec Historical Revenue Quarterly YoY Growth Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| March 31, 2013 | 9.53% |
| Dec. 31, 2012 | 6.88% |
| Sept. 30, 2012 | 5.77% |
| June 30, 2012 | 17.57% |
| March 31, 2012 | 7.37% |
| Dec. 31, 2011 | 8.83% |
| Sept. 30, 2011 | 11.41% |
| June 30, 2011 | -0.33% |
| March 31, 2011 | 8.52% |
| Dec. 31, 2010 | 8.16% |
| Sept. 30, 2010 | 4.93% |
| June 30, 2010 | 10.92% |
| March 31, 2010 | 6.98% |
| Dec. 31, 2009 | 5.44% |
| Sept. 30, 2009 | 2.52% |
| June 30, 2009 | 10.05% |
| March 31, 2009 | 10.01% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
BIIB Revenue Quarterly YoY Growth Benchmarks
| Companies | |
|---|---|
| Celgene Corporation | 15.02% |
| Gilead Sciences | 10.92% |
| Regeneron Pharmaceuticals | 89.68% |
BIIB Revenue Quarterly YoY Growth Rankings
| Overall |
78th percentile 1733 of 8007 |
| Sector |
68th percentile 213 of 685 in Healthcare |
| Industry |
74th percentile 64 of 248 in Biotechnology |
BIIB Revenue Quarterly YoY Growth Range, Past 5 Years
| Minimum | -0.33% | Jun 2011 |
| Maximum | 17.57% | Jun 2012 |
| Average | 7.92% |
